This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Open AccessArticle
Comparative Analysis of Ketorolac and Parecoxib for Postoperative Pain Management in Uvulopalatopharyngoplasty
by
Cheng-Yu Hsieh
Cheng-Yu Hsieh 1,2
,
Chuan-Hung Sun
Chuan-Hung Sun 1,2
,
Chung-Ching Lin
Chung-Ching Lin 1,2 and
Yi-Fan Chou
Yi-Fan Chou 1,2,*
1
Department of Otolaryngology, Head and Neck Surgery, Taichung Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taichung 427213, Taiwan
2
School of Medicine, Tzu Chi University, Hualien 970374, Taiwan
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2024, 13(15), 4422; https://doi.org/10.3390/jcm13154422 (registering DOI)
Submission received: 29 June 2024
/
Revised: 14 July 2024
/
Accepted: 26 July 2024
/
Published: 28 July 2024
Abstract
Background/Objectives: Uvulopalatopharyngoplasty (UPPP) is a prevalent surgical procedure for treating obstructive sleep apnea. Effective postoperative pain management is crucial for patient comfort and recovery. This study aimed to compare the analgesic efficacies of parecoxib and ketorolac in patients undergoing UPPP. Methods: A prospective, randomized, double-blind study was conducted on 83 patients who received either parecoxib (40 mg intravenously every 12 h) or ketorolac (30 mg intravenously every 8 h) for 2 days following UPPP. Postoperative pain and swallowing discomfort were assessed using visual analog scales (VASs) at 4, 24, 48, and 72 h. The time to resume eating and adverse reactions were also recorded. Results: At 24 and 48 h postoperatively, the mean VAS score was significantly higher in the ketorolac group compared to the parecoxib group (5.0 ± 2.3 vs. 3.6 ± 2.2, p = 0.005 and 3.9 ± 2.2 vs. 2.5 ± 1.7, p < 0.001, respectively). However, no significant difference in the mean VAS scores was observed between the two groups at 72 h postoperatively. With regards to postoperative swallowing pain, the ketorolac group exhibited significantly higher mean VAS scores than the parecoxib group at 4, 24, 48, and 72 h postoperatively. Conclusions: Intravenous parecoxib may offer superior analgesic benefits in the early postoperative period, particularly in alleviating swallowing pain, compared to ketorolac in UPPP procedures.
Share and Cite
MDPI and ACS Style
Hsieh, C.-Y.; Sun, C.-H.; Lin, C.-C.; Chou, Y.-F.
Comparative Analysis of Ketorolac and Parecoxib for Postoperative Pain Management in Uvulopalatopharyngoplasty. J. Clin. Med. 2024, 13, 4422.
https://doi.org/10.3390/jcm13154422
AMA Style
Hsieh C-Y, Sun C-H, Lin C-C, Chou Y-F.
Comparative Analysis of Ketorolac and Parecoxib for Postoperative Pain Management in Uvulopalatopharyngoplasty. Journal of Clinical Medicine. 2024; 13(15):4422.
https://doi.org/10.3390/jcm13154422
Chicago/Turabian Style
Hsieh, Cheng-Yu, Chuan-Hung Sun, Chung-Ching Lin, and Yi-Fan Chou.
2024. "Comparative Analysis of Ketorolac and Parecoxib for Postoperative Pain Management in Uvulopalatopharyngoplasty" Journal of Clinical Medicine 13, no. 15: 4422.
https://doi.org/10.3390/jcm13154422
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details
here.
Article Metrics
Article Access Statistics
For more information on the journal statistics, click
here.
Multiple requests from the same IP address are counted as one view.